

BIS

ProShares UltraShort Nasdaq Biotechnology

As of 06/30/2025

BIS seeks daily investment results, before fees and expenses, that correspond to two times the inverse (-2x) of the daily performance of the Nasdaq Biotechnology® Index.

Why BIS?



Profit from Market Downturns

BIS is the only -2x ETF designed to profit when the daily performance of the Biotechnology industry declines.



Portfolio Hedging

BIS provides the opportunity to offset an expected market decline.



Convenience

Buy and sell inverse exposure via a single ticker in a brokerage account.

KEY FACTS

Inception Date	04/07/10
Gross Expense Ratio	2.42%
Net Expense Ratio*	0.95%
Underlying Index	Nasdaq Biotechnology® Index

TRADING DETAILS

Fund Ticker	BIS
Intraday Symbol	BIS.IV
Bloomberg Index Ticker	XNBI
CUSIP	74347G838
Exchange	NASDAQ
Options Available	Yes

DISTRIBUTION DETAILS

Distribution Frequency	Quarterly
30-Day SEC Yield ¹	2.73%
30-Day SEC Yield (Unsub) ¹	0.17%
12-Month Yield ²	3.39%

PERFORMANCE (%)

	Q2 25	YTD	1 YR	3 YR	5 YR	10 YR	INCEPTION
BIS (NAV)	-4.62%	-1.61%	10.26%	-11.08%	-10.04%	-16.30%	-30.37%
BIS (Market Price)	-4.41%	-1.31%	10.14%	-11.05%	-10.02%	-16.30%	-30.36%
XNBI (Index)	-0.15%	-1.46%	-6.21%	4.94%	0.45%	1.55%	10.84%

Periods greater than one year are annualized.

BIS VS. INDEX: DAILY RETURN CORRELATION (Q2 25)



Correlation³ = -1.00


Beta⁴ = -2.00

The scatter plot charts the daily NAV-to-NAV results of the fund against its underlying index return on a daily basis.

Performance quoted represents past performance and does not guarantee future results. Investment return and principal value will fluctuate, so an investor's shares may be worth more or less than the original cost when sold. Market price returns are based on the bid/ask midpoint at 4:00 p.m. ET (when NAV is normally determined) and may differ from your returns if you traded shares at other times. Index performance does not reflect fees or expenses. Indexes are unmanaged and cannot be invested in directly. Current performance may be higher or lower than performance quoted. For performance data current to the most recent month-end, visit [ProShares.com](https://www.proshares.com).

TOP 10 INDEX CONSTITUENTS (%)

Gilead Sciences Inc.	7.77%
Vertex Pharmaceuticals Inc.	7.77%
Amgen Inc.	7.47%
AstraZeneca plc-Sponsored ADR	6.15%
Alnylam Pharmaceuticals Inc.	4.60%
Biogen Inc.	4.13%
Insmed Inc.	2.05%
argenx SE-ADR	2.04%
Summit Therapeutics Inc.	1.94%
Royalty Pharma plc-Class A	1.76%

INDEX SECTOR WEIGHTINGS (%)⁶**INDEX CHARACTERISTICS**

Number of Companies	260
Average Market Cap	\$5.68 billion
Price/Book Ratio	3.78
Volatility ⁵	32.76%

This ProShares ETF seeks daily investment results that correspond, before fees and expenses, to -2x the daily performance of its underlying benchmark (the "Daily Target"). While the Fund has a daily investment objective, you may hold Fund shares for longer than one day if you believe it is consistent with your goals and risk tolerance. For any holding period other than a day, your return may be higher or lower than the Daily Target. These differences may be significant. Smaller index gains/losses and higher index volatility contribute to returns worse than the Daily Target. Larger index gains/losses and lower index volatility contribute to returns better than the Daily Target. The more extreme these factors are, the more they occur together, and the longer your holding period while these factors apply, the more your return will tend to deviate. Investors should consider periodically monitoring their geared fund investments in light of their goals and risk tolerance.

*Expenses with Contractual Waiver through September 30, 2025. Without the fee waiver performance would likely be lower. ¹30-Day SEC Yield is a standard yield calculation that facilitates fairer fund comparisons. It reflects dividends and interest earned by the fund during the most recent 30-day period, net of fund expenses. Unsubsidized 30-Day SEC Yield represents the yield if the fund did not have a fee waiver. ²12-Month Yield represents the sum of the fund's dividends for the last 12 months divided by the sum of the last month's NAV and any capital gain distributions made over the past 12 months. ³"Correlation" is a measure of the strength and direction of a linear relationship between two variables. ⁴"Beta" is a measure of the slope, which is the steepness of the line drawn through the fund return vs. the benchmark return on a daily basis. ⁵"Volatility" refers to annualized standard deviation, a statistical measure that captures the variations from the mean of an index's returns and that is often used to quantify the risk of the index over a specific time period. The higher the volatility, the more an index's returns fluctuate over time. ⁶Sum of weightings may not equal 100% due to rounding.

"Nasdaq Biotechnology®" is a registered trademark of The Nasdaq OMX Group Inc. ("Nasdaq OMX") and has been licensed for use by ProShares. ProShares have not been passed on by Nasdaq OMX or its subsidiaries or affiliates as to their legality or suitability. ProShares are not sponsored, endorsed, sold, or promoted by Nasdaq OMX or its subsidiaries or affiliates, and they make no representation regarding the advisability of investing in these products.

NASDAQ OMX AND ITS SUBSIDIARIES AND AFFILIATES MAKE NO WARRANTIES AND BEAR NO LIABILITY WITH RESPECT TO PROSHARES.

The Global Industry Classification Standard ("GICS") was developed by and is the exclusive property of MSCI Inc. ("MSCI") and Standard & Poor's, a division of The McGraw-Hill Companies Inc. ("S&P"). Neither MSCI, S&P nor any third party involved in making or compiling GICS or any GICS classifications makes any express or implied warranties or representations with respect thereto (or the results to be obtained by the use thereof).

Carefully consider the investment objectives, risks, charges and expenses of ProShares before investing. This material must be preceded or accompanied by the current fund prospectus. Read it carefully before investing. Short ProShares should lose value when their market indexes rise—a result that is opposite from traditional ETFs.

Investing involves risk, including the possible loss of principal. ProShares are generally non-diversified and entail certain risks, including risk associated with the use of derivatives (swap agreements, futures contracts and similar instruments), imperfect benchmark correlation, leverage and market price variance. These risks may pose risks different from, or greater than, those associated with a direct investment in the securities underlying the funds' benchmarks, can increase volatility, and may dramatically decrease performance. Narrowly focused investments typically exhibit higher volatility. Technology companies may be subject to severe competition and product obsolescence. Please see the summary and full prospectuses for a more complete description of risks.

There is no guarantee any ProShares ETF will achieve its investment objective.

ProShares may invest in equity securities and/or financial instruments (including derivatives) that, in combination, should have similar daily price return characteristics to the fund's benchmark. Derivative contracts are priced to include the underlying index yield and will not generate dividend income. Because ProShares invest in derivatives and other financial instruments, their dividend distributions may not reflect those of their applicable indexes.

Shares of any ETF are generally bought and sold at market price (not NAV) and are not individually redeemed from the fund. Your brokerage commissions will reduce returns. ProShares are distributed by SEI Investments Distribution Co., which is not affiliated with the fund's advisor.